(Q38018673)

27 August 2017

title

Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

27 August 2017

main subject

0 references

multiple sclerosis

0 references

author name string

Wolfgang Brück

series ordinal

1

1 reference

27 August 2017

Scott S Zamvil

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 May 2012

1 reference

Expert Review of Clinical Pharmacology

27 August 2017

published in

1 reference

27 August 2017

volume

5

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

245-256

1 reference

Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications.

27 August 2017

cites work

1 reference

Pathophysiology of inflammation and tissue injury in multiple sclerosis: what are the targets for therapy

21 January 2018

1 reference

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

21 January 2018

1 reference

Development of oral immunomodulatory agents in the management of multiple sclerosis

21 January 2018

1 reference

Emerging oral therapies in multiple sclerosis

21 January 2018

1 reference

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

21 January 2018

1 reference

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy

21 January 2018

1 reference

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

21 January 2018

1 reference

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

21 January 2018

1 reference

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis

21 January 2018

1 reference

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study

21 January 2018

1 reference

Strain-specific susceptibility for neurodegeneration in a rat model of autoimmune optic neuritis

21 January 2018

1 reference

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor

21 January 2018

1 reference

In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species

21 January 2018

1 reference

Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator

21 January 2018

1 reference

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

Factor V Leiden related Budd-Chiari syndrome

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.12.12

1 reference

27 August 2017

1 reference